IPP Bureau

Reliance Life Sciences appoints Siva Sankar Mahamkali as VP Biosimilars Manufacturing Operations
Reliance Life Sciences appoints Siva Sankar Mahamkali as VP Biosimilars Manufacturing Operations

By IPP Bureau - May 22, 2026

Biologics manufacturing veteran brings over two decades of expertise in biosimilars, GMP operations, and large-scale biopharmaceutical manufacturing

Dr. Amit Arora joins Curelo as Co-founder & COO
Dr. Amit Arora joins Curelo as Co-founder & COO

By IPP Bureau - May 22, 2026

Diagnostic-guided healthcare platform strengthens leadership team to accelerate AI-driven diagnostics and consumer healthcare expansion

Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore
Aurobindo Pharma Q4 FY26 revenue rises 5.6% to Rs. 8,853 crore

By IPP Bureau - May 22, 2026

Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore

Dr. Agarwal’s crosses Rs. 2,000 crore revenue milestone in FY26
Dr. Agarwal’s crosses Rs. 2,000 crore revenue milestone in FY26

By IPP Bureau - May 22, 2026

Eye care major expands network to 288 facilities across 10 countries after adding 57 new centres during FY26

Venus Remedies secures global approval for Plerixafor in Saudi Arabia
Venus Remedies secures global approval for Plerixafor in Saudi Arabia

By IPP Bureau - May 22, 2026

SFDA nod marks company’s strategic entry into high-value specialty oncology injectables as it targets expanding stem cell transplant and haemato-oncology market in the GCC region

Alembic Pharma receives USFDA nod for generic Levothyroxine sodium tablets
Alembic Pharma receives USFDA nod for generic Levothyroxine sodium tablets

By IPP Bureau - May 22, 2026

Approved product is therapeutically equivalent to Synthroid of AbbVie and is indicated for the treatment of congenital or acquired hypothyroidism

Lupin enters China market with approval for Oseltamivir oral suspension
Lupin enters China market with approval for Oseltamivir oral suspension

By IPP Bureau - May 22, 2026

The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment

Sun Pharma reports FY26 revenue of Rs. 58,220 crore, net profit at Rs. 11,479 crore
Sun Pharma reports FY26 revenue of Rs. 58,220 crore, net profit at Rs. 11,479 crore

By IPP Bureau - May 22, 2026

Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth

Jubilant Pharmova posts 14% FY26 revenue growth to Rs. 8,280 crore amid margin pressure
Jubilant Pharmova posts 14% FY26 revenue growth to Rs. 8,280 crore amid margin pressure

By IPP Bureau - May 22, 2026

Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum

APHI welcomes CCI order on integrated healthcare delivery model
APHI welcomes CCI order on integrated healthcare delivery model

By IPP Bureau - May 22, 2026

The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices

IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26
IOLCP revenue rises 11.5% YoY to Rs. 2,319.1 crore in FY26

By IPP Bureau - May 21, 2026

Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore

Takeda Pharma ordered to pay $2.5 billion in Amitiza case
Takeda Pharma ordered to pay $2.5 billion in Amitiza case

By IPP Bureau - May 21, 2026

US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza

Boehringer Ingelheim India signs MoUs with NIPER Ahmedabad and Hyderabad to expand research collaboration
Boehringer Ingelheim India signs MoUs with NIPER Ahmedabad and Hyderabad to expand research collaboration

By IPP Bureau - May 21, 2026

This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access

Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%
Eris Lifesciences reports Q4 FY26 revenue of Rs. 757 crore; PAT jumps 173%

By IPP Bureau - May 21, 2026

Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth

Apollo, Cloudnine merge maternity and fertility businesses in Rs. 1,550 crore deal
Apollo, Cloudnine merge maternity and fertility businesses in Rs. 1,550 crore deal

By IPP Bureau - May 21, 2026

Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India

Latest Stories

Interviews

Packaging